KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Issued (2016 - 2025)

Sarepta Therapeutics has reported Shares Issued over the past 15 years, most recently at $2.8 million for Q3 2025.

  • Quarterly results put Shares Issued at $2.8 million for Q3 2025, up 104.54% from a year ago — trailing twelve months through Dec 2025 was -$59.2 million (changed N/A YoY), and the annual figure for FY2025 was $20.0 million, changed.
  • Shares Issued for Q3 2025 was $2.8 million at Sarepta Therapeutics, up from -$62.1 million in the prior quarter.
  • Over the last five years, Shares Issued for SRPT hit a ceiling of $39.9 million in Q2 2024 and a floor of -$62.1 million in Q3 2024.
  • Median Shares Issued over the past 5 years was $5.9 million (2021), compared with a mean of $3.4 million.
  • Peak annual rise in Shares Issued hit 1628.91% in 2023, while the deepest fall reached 536.19% in 2023.
  • Sarepta Therapeutics' Shares Issued stood at $2.1 million in 2021, then surged by 426.21% to $11.3 million in 2022, then plummeted by 536.19% to -$49.3 million in 2023, then dropped by 25.87% to -$62.1 million in 2024, then soared by 104.54% to $2.8 million in 2025.
  • The last three reported values for Shares Issued were $2.8 million (Q3 2025), -$62.1 million (Q3 2024), and $39.9 million (Q2 2024) per Business Quant data.